More Biotech Deal-Making Lifts a few ETFs

The three largest biotechnology exchange traded funds are down over the past month by an average, gasp, 1.6%. That modest number has been enough to elicit the tired fears that sector is richly valued and overdue for a more significant pullback. There is nothing like some more biotech mergers and...